<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tension-type headache in adults: Acute treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tension-type headache in adults: Acute treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tension-type headache in adults: Acute treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Frederick R Taylor, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tension-type headache (TTH) is characterized by bilateral, nonthrobbing head pain of a mild to moderate intensity, typically without other associated features. TTH is the most common headache and prevalent neurologic disorder in the population. Due to its high prevalence, TTH is associated with a significant burden of disability.</p><p>The acute treatment of TTH in adults is reviewed here. Other aspects of TTH are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3357.html" rel="external">"Tension-type headache in adults: Etiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3360.html" rel="external">"Tension-type headache in adults: Preventive treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6160.html" rel="external">"Tension-type headache in children"</a>.)</p><p></p><p class="headingAnchor" id="H2060511782"><span class="h1">GOALS OF TREATMENT</span><span class="headingEndMark"> — </span>Effective acute treatment of TTH should result in sustained improvement or resolution of headache pain. Validated criteria for judging the effectiveness of acute TTH therapy in clinical practice are not yet available, but such criteria do exist for acute migraine treatment [<a href="#rid1">1</a>]. In the absence of specific TTH measures, the migraine criteria can be used by clinicians to assess the success of acute TTH treatment and to identify patients who may benefit from a change in therapy. Reasonable goals for an acute TTH treatment regimen include:</p><p class="bulletIndent1"><span class="glyph">●</span>Headache pain resolves promptly (eg, within two to four hours of treatment)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptom resolution is durable (ie, is disability limited) without recurrence</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Headaches respond to acute treatment consistently (ie, ≥75 percent of the time)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tolerable medication administration, adverse effects, and cost</p><p></p><p>The treatment should be considered ineffective if two or more of these criteria are not met.</p><p class="headingAnchor" id="H3948096056"><span class="h1">INITIAL TREATMENT</span><span class="headingEndMark"> — </span>Acute treatment of TTH is most commonly self-directed using over-the-counter medications without any input from a medical provider. For the vast majority of patients affected by TTH requiring medical care, primary care can and should provide management [<a href="#rid2">2</a>].</p><p>TTH that is refractory to initial treatment options may warrant diagnostic evaluation or referral to a specialist. (See <a class="local">'Diagnostic reevaluation'</a> below.)</p><p class="headingAnchor" id="H3119328645"><span class="h2">General treatment principles</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treat early</strong> – Acute TTH treatment is felt to be most effective if given early after onset of symptoms. However, data to support this principle are based on timing of abortive therapy for patients with migraine as no valid data exist for patients with TTH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use effective initial dose</strong> – Treatment should be individualized using an effective initial dose. Starting with the maximum medication dose in acute therapy is customary, with the goal of limiting subsequent repeat dosing. However, there is no definitive evidence to support this principle, even though a dose-ranging curve likely exists with simple analgesics [<a href="#rid3">3,4</a>]. Some patients obtain effective pain relief with a low analgesic dose. Others may prefer a low dose to minimize the risk of adverse effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limit dosing frequency of acute treatment</strong> – The frequency of acute treatment should be limited to avoid medication overuse headache. Simple analgesics such as nonsteroidal antiinflammatory drugs (NSAIDs) should be used 14 or fewer days a month, combination analgesics nine or fewer days a month, and butalbital-containing analgesics three or fewer days a month. (See  <a class="medical medical_review" href="/d/html/3341.html" rel="external">"Medication overuse headache: Treatment and prognosis", section on 'Follow-up and relapse prevention'</a>.)</p><p></p><p class="headingAnchor" id="H1378733937"><span class="h2">Simple analgesics for most patients</span><span class="headingEndMark"> — </span>For most patients with episodic TTH (&lt;15 headaches a month), we recommend initial treatment with simple analgesics such as an NSAID or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>  (<a class="graphic graphic_algorithm graphicRef140039" href="/d/graphic/140039.html" rel="external">algorithm 1</a>). We typically treat as early as possible after headache onset for optimal efficacy. For patients with symptoms unresponsive to initial choice of therapy, we switch to a different analgesic option.</p><p>For patients who cannot tolerate NSAIDs or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, we recommend a single dose of <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>. (See <a class="local">'Acetaminophen'</a> below.)</p><p class="headingAnchor" id="H4193774311"><span class="h3">NSAIDs or aspirin</span><span class="headingEndMark"> — </span>Nonsteroidal antiinflammatory drugs (NSAIDs) and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> are effective for mild to moderate symptoms in TTH. Reasonable initial choices for acute TTH include a single dose of:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">Ibuprofen</a> (400 to 600 mg)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">Naproxen</a> sodium (220 to 550 mg)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> (500 to 650 mg)</p><p></p><p>For those unresponsive to or unable to take initial options, <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> (25 to 100 mg) and <a class="drug drug_general" data-topicid="8590" href="/d/drug information/8590.html" rel="external">ketoprofen</a> (25 to 50 mg) are potential alternatives.</p><p>Available evidence from clinical trials and systematic reviews supports the use of simple analgesic agents in the acute treatment of TTH [<a href="#rid5">5-11</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – NSAIDs appear to have similar effectiveness for TTH when compared with each other in clinical trials [<a href="#rid6">6,8,12-16</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">Ibuprofen</a>, <a class="drug drug_general" data-topicid="8590" href="/d/drug information/8590.html" rel="external">ketoprofen</a>, and <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> are the best studied agents. In a systematic review of 12 studies including 3094 patients with acute TTH, ibuprofen 400 mg was found to be more effective than placebo at two hours and was well tolerated, with adverse effects that were both minor and similar to placebo [<a href="#rid10">10</a>]. In available studies, the proportion of patients reporting very good or excellent response was 40 percent for ibuprofen compared with 23 percent for placebo. Naproxen at 375 mg was found to have similar efficacy to <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> 1000 mg [<a href="#rid17">17</a>], and naproxen sodium at 550 mg was found to have similar efficacy to acetaminophen 1000 mg with <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8590" href="/d/drug information/8590.html" rel="external">Ketoprofen</a> at 25 mg also appears to be effective with studies reporting similar efficacy to <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> 1000 mg, <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> 200 mg, and <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> sodium 275 mg [<a href="#rid13">13,19,20</a>]. Among the NSAIDs less studied for treating TTH, one trial found that <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> (12.5 mg and 25 mg) was effective for episodic TTH compared with placebo [<a href="#rid16">16</a>], but no trials have evaluated diclofenac at the higher doses of 50 to 100 mg that were effective in migraine [<a href="#rid6">6,16</a>].</p><p></p><p class="bulletIndent1">NSAIDs were found to be more effective for TTH than <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> in several [<a href="#rid19">19-23</a>], but not all [<a href="#rid3">3,17,24</a>], trials.</p><p></p><p class="bulletIndent1">Although simple analgesics and NSAIDs are useful for episodic TTH, their effectiveness is modest, with pain-free rates at two hours ranging from 16 to 37 percent [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1">Some experts also consider <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> as first-line therapy for TTH, but there are few trials comparing aspirin with other analgesics for this indication [<a href="#rid25">25</a>]. In a systematic review of five trials including 1812 patients with acute TTH, a single dose of aspirin at 500 or 1000 mg was well tolerated, more effective than placebo, and was associated with a lower rate of subsequent rescue medications (14 versus 31 percent) [<a href="#rid26">26</a>]. However, the certainty of these results is limited by varying treatment doses, different measures of efficacy, and small numbers of events available for analysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Systematic reviews of randomized controlled trials concluded that <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> 1000 mg, <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> 400 mg, and <a class="drug drug_general" data-topicid="8590" href="/d/drug information/8590.html" rel="external">ketoprofen</a> 25 mg were more effective than placebo using the preferred efficacy parameter of pain-free rates at two hours [<a href="#rid5">5,10</a>]. In addition, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>, and <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> at typically used doses were each likely more effective than placebo.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> also has been reported to be more effective than placebo in doses of 500 to 1000 mg [<a href="#rid3">3,6,26</a>]. One study demonstrated a significant dose-response relationship of aspirin with 1000 mg being superior to 500, and 500 mg being superior to 250 mg [<a href="#rid4">4</a>]. In addition, an early trial found that nearly 650 mg of either solid or effervescent aspirin was more effective than placebo for the treatment of TTH with similar efficacy for the two forms of aspirin [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – NSAIDs are associated with risks of cardiovascular events and kidney injury, and both NSAIDs and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> increase the risk of gastrointestinal bleeding. In studies of patients with acute TTH, NSAIDs and aspirin were generally well tolerated. Systematic reviews concluded that <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> for acute treatment of TTH is associated with only mild adverse effects at rates lower than other NSAIDs and similar to placebo [<a href="#rid8">8,10</a>]. NSAIDs and aspirin are less likely to lead to medication overuse headache than other commonly used analgesics, such as butalbital, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, and <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a> [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p></p><p class="headingAnchor" id="H2457678611"><span class="h3">Acetaminophen</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> (paracetamol) is preferred initial therapy for patients with TTH who are unable to tolerate or have contraindications to NSAIDs or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and for pregnant patients. Acetaminophen is typically used at 500 to 1000 mg as a single oral dose.</p><p>Some experts consider <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> first-line therapy for TTH, based on similar efficacy with NSAIDs in some trials. Acetaminophen 1000 mg was significantly more effective than placebo in most trials while smaller doses were not superior to placebo [<a href="#rid9">9</a>]. As an example, one trial evaluated 638 subjects from the United Kingdom aged 16 to 65 years with episodic TTH [<a href="#rid3">3</a>]. More than 70 percent of patients who received <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or paracetamol 1000 mg reported pain relief by two hours, but the response rate with paracetamol 500 mg was similar to placebo (64 versus 55 percent).</p><p>However, other trials have failed to find similar efficacy of <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> with other NSAIDs. As an example, one trial of 703 patients with TTH were assigned to acetaminophen 1000 mg, <a class="drug drug_general" data-topicid="8590" href="/d/drug information/8590.html" rel="external">ketoprofen</a> 12.5 mg, or ketoprofen 25 mg [<a href="#rid19">19</a>]. Rates of pain relief at four hours were higher for patients who received either dose of ketoprofen than those assigned to placebo. However, pain relief for those assigned to acetaminophen was similar to placebo.</p><p><a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> is generally well tolerated but is contraindicated for patients with severe liver disease. Acetaminophen is also associated with an elevated risk of liver injury when taken at doses above the therapeutic range. (See  <a class="medical medical_review" href="/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation"</a>.)</p><p class="headingAnchor" id="H3513477979"><span class="h2">Parenteral analgesics or antiemetics for severe symptoms</span><span class="headingEndMark"> — </span>For patients with severe or disabling TTH unresponsive to an initial self-administered simple analgesic who present to an emergency department (ED) or other setting where parenteral medications can be administered, we suggest a single dose of an antiemetic or analgesic medication by intravenous (IV) or intramuscular (IM) route  (<a class="graphic graphic_algorithm graphicRef140039" href="/d/graphic/140039.html" rel="external">algorithm 1</a>). While migraine is the most common headache among patients presenting to an ED, some patients with severe TTH may present for treatment when simple analgesics taken prior to presenting are ineffective. Parenteral medications may provide more rapid pain relief than oral agents. Options include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8591" href="/d/drug information/8591.html" rel="external">Ketorolac</a> 30 mg IV or 60 mg IM (a reduced dose of ketorolac 15 mg IV or 30 mg IM is used for patients weighing &lt;50 kg or &gt;64 years old)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">Metoclopramide</a> 10 mg IV</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9252" href="/d/drug information/9252.html" rel="external">Chlorpromazine</a> 12.5 mg IV (given over 15 minutes)</p><p></p><p><a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">Diphenhydramine</a> (12.5 to 25 mg IV) may be given along with an antiemetic medication to prevent akathisia and other dystonic reactions.</p><p>There is limited evidence from small, low-quality trials regarding the efficacy of parenteral treatments for acute TTH [<a href="#rid29">29</a>]. A systematic review of trials that included patients with various types of TTH (episodic, chronic, and unknown frequency) concluded that parenteral medications more effective than placebo for acute relief of TTH include <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>, <a class="drug drug_general" data-topicid="9252" href="/d/drug information/9252.html" rel="external">chlorpromazine</a>, and metamizole; comparative data were limited to the combination of metoclopramide plus <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, which was found to be superior to <a class="drug drug_general" data-topicid="8591" href="/d/drug information/8591.html" rel="external">ketorolac</a> [<a href="#rid30">30</a>]. Metamizole is not available in many countries, including the United States, because it is associated with a risk of agranulocytosis.</p><p>IM <a class="drug drug_general" data-topicid="8591" href="/d/drug information/8591.html" rel="external">ketorolac</a> may be effective for moderate to severe acute TTH, but data are limited to a trial involving 41 patients with TTH (but only 18 with episodic TTH) who were randomly assigned to treatment with either IM ketorolac 60 mg, <a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">meperidine</a> 50 mg plus <a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">promethazine</a> 25 mg, or normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> [<a href="#rid31">31</a>]. Ketorolac treatment was significantly more effective than placebo at 30 minutes and one hour and more effective than meperidine plus promethazine at two hours.</p><p class="headingAnchor" id="H3841407353"><span class="h2">Patients with chronic tension-type headache</span><span class="headingEndMark"> — </span>For patients who present acutely with chronic TTH (≥15 headache days a month), we start a preventive treatment agent in addition to acute treatment options. Analgesics or antiemetics may be used for patients with chronic TTH presenting with acute symptoms. However, acute treatment options alone may be ineffective for patients with chronic TTH. Such patients have a high rate of comorbid conditions such as anxiety and depression. In addition, patients are at risk for medication overuse headache. (See  <a class="medical medical_review" href="/d/html/3360.html" rel="external">"Tension-type headache in adults: Preventive treatment", section on 'Indication for preventive treatment'</a>.)</p><p class="headingAnchor" id="H441182975"><span class="h1">MANAGEMENT OF PATIENTS WITH PERSISTING SYMPTOMS</span><span class="headingEndMark"> — </span>For patients who do not respond to initial treatment options, we reevaluate the diagnosis to assess for other headache conditions that may also present with bilateral nonthrobbing head pain. For those with TTH, we typically offer combination therapy.</p><p class="headingAnchor" id="H2599900864"><span class="h2">Diagnostic reevaluation</span><span class="headingEndMark"> — </span>When acute treatment of TTH is ineffective, multiple factors may be contributing. The patient may have refractory TTH or the diagnostic impression of episodic TTH may be incorrect. Alternative causes of headache that may require different treatment strategies should be assessed.</p><p class="bulletIndent1"><span class="glyph">●</span>Common alternative diagnoses include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Migraine without aura</strong> – Migraine without aura is the most common alternative diagnosis for patients unresponsive to TTH initial treatment. Diagnostic misattribution may be due to underreporting of migraine symptoms or baseline disability of the patient or from failure of the clinician to consider migraine. In one study of 423 adults who were evaluated in headache clinics for self-reported tension headache, 65 percent were determined to have migraine and 84 percent met criteria for both migraine and TTH [<a href="#rid32">32</a>]. Migraine without aura is likelier to cause unilateral and pulsatile symptoms and is frequently associated with nausea, vomiting, photophobia, or phonophobia  (<a class="graphic graphic_table graphicRef50876" href="/d/graphic/50876.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/3348.html" rel="external">"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic tension-type headache</strong> – Chronic TTH refers to TTH that occurs ≥15 days a month on average for at least three months [<a href="#rid33">33</a>]. Chronic TTH is less responsive to acute therapies than episodic TTH and is often associated with comorbid stress, anxiety, and depression [<a href="#rid34">34</a>]. In this setting, preventive therapy is typically indicated. Parenteral analgesic or antiemetic agents may be tried for patients with severe acute symptoms, but acute treatment options alone are usually of little or no benefit. (See  <a class="medical medical_review" href="/d/html/3360.html" rel="external">"Tension-type headache in adults: Preventive treatment", section on 'Indication for preventive treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medication overuse headache</strong> – Some patients with frequent episodes of TTH may also develop medication overuse headache due to excessive use of acute therapies  (<a class="graphic graphic_table graphicRef71798" href="/d/graphic/71798.html" rel="external">table 2</a>). Several medications may cause medication overuse headache including opioids, butalbital-containing combination analgesics, triptans, and simple analgesics. Symptoms attributable to medication overuse headache typically resolve following successful withdrawal of the offending agent. (See  <a class="medical medical_review" href="/d/html/3340.html" rel="external">"Medication overuse headache: Etiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary headaches</strong> – Headaches may be due to several other conditions, including brain tumor, stroke, intracranial hypertension, glaucoma, and giant cell arteritis. The presence of clinical history or features atypical for TTH or abnormalities on neurologic or systemic examination may suggest the possibility of secondary headaches  (<a class="graphic graphic_table graphicRef78567" href="/d/graphic/78567.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/3349.html" rel="external">"Evaluation of headache in adults", section on 'Danger signs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In some instances, the diagnosis of episodic TTH is correct and effective acute treatment has been administered, but the patient has unrealistic expectations of therapy (eg, an expectation of freedom from pain within 10 minutes of using an analgesic medication). Education on the expected time of onset of efficacy for headache treatments may be warranted to avoid unnecessary additional treatment and risk of medication overuse headache. (See <a class="local">'Goals of treatment'</a> above.)</p><p></p><p>The differential diagnosis of TTH is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/3357.html" rel="external">"Tension-type headache in adults: Etiology, clinical features, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H4068284395"><span class="h2">Treatment for patients with refractory symptoms</span><span class="headingEndMark"> — </span>For patients with episodic TTH unresponsive to initially administered treatment options, we use combination analgesic therapy along with another agent such as <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a>  (<a class="graphic graphic_algorithm graphicRef140039" href="/d/graphic/140039.html" rel="external">algorithm 1</a>).</p><p>Adjunctive preventive therapy may be warranted for patients with prolonged acute or worsening TTH. (See <a class="local">'Adjunctive preventive options'</a> below.)</p><p class="headingAnchor" id="H2296715209"><span class="h3">Combination analgesics with caffeine</span><span class="headingEndMark"> — </span>For most patients with episodic TTH refractory to simple analgesics, we suggest the use of <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> 130 mg combined with simple analgesics such as a nonsteroidal antiinflammatory drug (NSAID) or <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>. A reasonable choice is a single dose of two tablets of combined acetaminophen 250 mg, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> 250 mg, and caffeine 65 mg.</p><p>The combination of <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> with simple analgesics is more effective for the treatment of episodic TTH than simple analgesics alone. Several trials have assessed the efficacy of NSAIDs with caffeine [<a href="#rid35">35,36</a>]. In a multicenter trial of 385 patients with TTH that assessed <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> with caffeine, combination therapy was more effective than ibuprofen 400 mg alone, caffeine 200 mg alone, and placebo [<a href="#rid36">36</a>]. The proportion of patients who reported complete pain relief by six hours was 71 percent for combination therapy compared with 58 percent each for ibuprofen or caffeine alone and 48 percent for placebo. Adverse effects with combination therapy were common but typically mild, including nausea, abdominal pain, and dizziness.</p><p>The fixed combination of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>, <a class="drug drug_general" data-topicid="9816" href="/d/drug information/9816.html" rel="external">prochlorperazine</a>, and <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> was more effective than nimesulide (an NSAID) for pain-free relief at two hours (45 versus 10 percent) in a trial of 54 patients with TTH [<a href="#rid37">37</a>]. Patients assigned to combination therapy were likelier to be pain-free at two hours (45 versus 10 percent) and four hours (90 versus 58 percent).</p><p><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> has also been found to be effective when combined with <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a>. A trial of 1743 patients with episodic TTH found the combination <a class="drug drug_general" data-topicid="9192" href="/d/drug information/9192.html" rel="external">acetaminophen-aspirin-caffeine</a> (400 mg-500 mg-100 mg) was more effective than the combination without caffeine and to monotherapy with aspirin, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, caffeine, or placebo [<a href="#rid38">38</a>].</p><p>In multiple clinical trials, the combination <a class="drug drug_general" data-topicid="9192" href="/d/drug information/9192.html" rel="external">acetaminophen-aspirin-caffeine</a> (500 or 1000 mg-500 mg-130 mg) was more effective for the treatment of episodic TTH than <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> alone or placebo [<a href="#rid39">39</a>]. However, combination agents had more adverse effects (mainly gastrointestinal discomfort and dizziness) than acetaminophen alone.</p><p>Addition of <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> may enhance effects of analgesics for TTH but increase the risk of adverse effects such as abdominal pain and dizziness [<a href="#rid40">40-42</a>]. Chronic use of caffeine-containing analgesics can lead to rebound headache.</p><p class="headingAnchor" id="H3265784804"><span class="h3">Limited role of combination analgesics containing barbiturates or opioids</span><span class="headingEndMark"> — </span>We recommend <strong>against</strong> the routine use of opioids or barbiturates for treatment of TTH, in agreement with guidelines [<a href="#rid6">6</a>]. We reserve use of combination analgesic therapy with butalbital or opioids for highly selected patients with episodic TTH who are unresponsive to simple analgesics or combination analgesics with <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> when dose limits have been established and monitoring of therapy is in place. In addition, treatment may also be used for selected patients who are unable take NSAIDs or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> due to gastric ulcers or kidney failure or <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> due to liver failure [<a href="#rid43">43</a>].</p><p>Opioids and barbiturates are known to increase propensity for overuse, which can cause or contribute to the transformation of episodic TTH to chronic TTH and medication overuse headache [<a href="#rid44">44</a>]. Furthermore, these agents have the potential for the development of tolerance, dependency, and toxicity. Therefore, neither opioids nor barbiturates should be used in TTH when better options (eg, simple analgesics and combination analgesics containing <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a>) are available. There are no comparative studies examining the efficacy of combination analgesics with <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a> [<a href="#rid6">6</a>].</p><p>When practitioners encounter patients who are using opioids and barbiturates inappropriately for TTH, a "stop or brake" policy should be instituted and firmly maintained. The use of these medications is either stopped, or the frequency of use is braked by limiting the dose to no more than two days per week and an absolute maximum of six tablets per day up to three days per month.</p><p class="headingAnchor" id="H2815907784"><span class="h3">Adjunctive preventive options</span></p><p class="headingAnchor" id="H566921192"><span class="h4">Prophylactic therapy</span><span class="headingEndMark"> — </span>Preventive treatment may also be indicated for patients with TTH that worsens in severity or disability despite effective acute treatment. Patients with episodic TTH who request an increase in the amount or dose of effective acute medications may warrant "preemptive" prophylaxis treatment to reduce the risk of developing chronic TTH or medication overuse headache.</p><p>Patients may also prefer to start prophylactic therapy if headaches are frequent (eg, &gt;2 TTHs each month) or of long duration (eg, &gt;4 hours) and only partially responsive to acute therapies.</p><p>Preventive treatment of TTH is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/3360.html" rel="external">"Tension-type headache in adults: Preventive treatment"</a>.)</p><p class="headingAnchor" id="H3150083795"><span class="h4">Treat comorbid conditions</span><span class="headingEndMark"> — </span>Conditions associated with TTH may require treatment separate from strategies for TTH [<a href="#rid45">45</a>]. Depression and/or anxiety disorders may be comorbid with and triggers for TTH. In addition, the burden of TTH may contribute to depression or anxiety. Migraine and TTH may also coexist and can require separate treatments to achieve (combined) headache relief. (See  <a class="medical medical_review" href="/d/html/3357.html" rel="external">"Tension-type headache in adults: Etiology, clinical features, and diagnosis", section on 'Risk factors'</a> and  <a class="medical medical_review" href="/d/html/3357.html" rel="external">"Tension-type headache in adults: Etiology, clinical features, and diagnosis", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H1735132361"><span class="h3">Treatments of uncertain or dubious benefit</span><span class="headingEndMark"> — </span>Several other medications have also been used for acute treatment of TTH, including triptans, muscle relaxants, trigger point injections, and nonpharmacologic therapies.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Triptans</strong> – Data are limited and conflicting regarding the value of triptans for TTH. A small trial found that <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> 2 mg or 4 mg given subcutaneously had a modest beneficial effect in patients reported to have chronic TTH [<a href="#rid46">46</a>]. However, another study found that sumatriptan 100 mg tablet was no better than placebo for the treatment of episodic TTH [<a href="#rid47">47</a>]. European guidelines for TTH published in 2010 concluded that triptans most likely do not have a clinically relevant effect in patients with TTH [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">Other studies in patients with both TTH and migraine have reported some benefit with triptans [<a href="#rid48">48,49</a>]. It is unclear if the benefit is due to the effect of triptans on TTH or on migraine. Headaches regarded as TTH may be a mild form of migraine in these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Muscle relaxants</strong> – We do <strong>not</strong> use muscle relaxants for acute treatment of TTH. These agents are not considered effective and have a risk of habituation; there are no adequate controlled trials available to support the use of muscle relaxants for the treatment of TTH [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local injections</strong> – Trigger point injections using <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> of botulinum toxin have been used for preventive TTH treatment. Their role for acute treatment of TTH is uncertain. Local injections for prevention of TTH are discussed separately. (See  <a class="medical medical_review" href="/d/html/3360.html" rel="external">"Tension-type headache in adults: Preventive treatment", section on 'Local injection treatments'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpharmacologic therapies</strong> – Nonpharmacologic management is a widely used option for preventive therapy for patients with frequent episodic or chronic TTH. However, the evidence for efficacy of most modalities for acute TTH is sparse. Nonpharmacologic acute interventions for TTH include heat, ice, massage, rest, and biofeedback. The use of biofeedback and other nonpharmacologic strategies for preventive treatment of TTH are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/3360.html" rel="external">"Tension-type headache in adults: Preventive treatment", section on 'Behavioral therapies'</a>.)</p><p></p><p class="headingAnchor" id="H1663345414"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110285.html" rel="external">"Society guideline links: Migraine and other primary headache disorders"</a>.)</p><p class="headingAnchor" id="H3879856"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/720.html" rel="external">"Patient education: Headache treatment in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of treatment</strong> – Goals for an acute TTH treatment regimen include resolution of pain within two to four hours of treatment, durable pain relief without subsequent recurrence symptoms, and consistent effective response to therapy with subsequent TTH episodes. The medication regimen should be well tolerated. (See <a class="local">'Goals of treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Simple analgesics for most patients</strong> – For most patients with episodic TTH (&lt;15 headaches a month), we recommend treatment with simple analgesics such as a nonsteroidal antiinflammatory drug (NSAID) or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>  (<a class="graphic graphic_algorithm graphicRef140039" href="/d/graphic/140039.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> (paracetamol) is preferred initial therapy for patients with TTH who are unable to tolerate NSAIDs or aspirin and for pregnant patients. Single-dose oral options include (see <a class="local">'NSAIDs or aspirin'</a> above and <a class="local">'Acetaminophen'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">Ibuprofen</a> (400 to 600 mg)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">Naproxen</a> sodium (220 to 550 mg)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> (500 to 650 mg)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> (500 to 1000 mg)</p><p></p><p class="bulletIndent2">For patients with symptoms unresponsive to initial choice of therapy, we switch to a different analgesic option. We typically treat as early as possible after headache onset.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with severe symptoms</strong> – For patients with severe or disabling TTH unresponsive to an initial self-administered simple analgesic who present to an emergency department (ED) or other setting where parenteral medications can be administered, we suggest a single dose of an antiemetic or analgesic medication by intravenous (IV) or intramuscular (IM) route  (<a class="graphic graphic_algorithm graphicRef140039" href="/d/graphic/140039.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Parenteral medications may provide more rapid pain relief than oral agents. Options include (see <a class="local">'Parenteral analgesics or antiemetics for severe symptoms'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8591" href="/d/drug information/8591.html" rel="external">Ketorolac</a> 30 mg IV or 60 mg IM (a reduced dose of ketorolac 15 mg IV or 30 mg IM is used for patients weighing &lt;50 kg or &gt;64 years old)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">Metoclopramide</a> 10 mg IV</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9252" href="/d/drug information/9252.html" rel="external">Chlorpromazine</a> 12.5 mg IV (given over 15 minutes)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">Diphenhydramine</a> (12.5 to 25 mg IV) may be given along with an antiemetic medication to prevent akathisia and other dystonic reactions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with chronic symptoms</strong> – For patients who present acutely with chronic TTH (≥15 headache days a month), we start preventive treatment in addition to analgesics or antiemetics for acute symptoms. Analgesics or antiemetics alone may be ineffective for patients with chronic TTH. (See <a class="local">'Patients with chronic tension-type headache'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients unresponsive to initial treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reevaluate the diagnosis</strong> – For patients who do not respond to initial treatment options, we reevaluate the diagnosis to assess for other headache conditions that may also present with bilateral nonthrobbing head pain. Common alternative diagnoses include (see <a class="local">'Diagnostic reevaluation'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Migraine without aura  (<a class="graphic graphic_table graphicRef50876" href="/d/graphic/50876.html" rel="external">table 1</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Chronic TTH</p><p class="bulletIndent3"><span class="glyph">-</span>Medication overuse headache  (<a class="graphic graphic_table graphicRef71798" href="/d/graphic/71798.html" rel="external">table 2</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Secondary causes of headaches  (<a class="graphic graphic_table graphicRef78567" href="/d/graphic/78567.html" rel="external">table 3</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute treatment for refractory symptoms</strong> – For most patients with episodic TTH refractory to simple analgesics, we suggest the use of <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> combined with simple analgesics  (<a class="graphic graphic_algorithm graphicRef140039" href="/d/graphic/140039.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_4" rel="external">Grade 2A</a>). One such regimen is a single dose of two tablets of combined <a class="drug drug_general" data-topicid="9192" href="/d/drug information/9192.html" rel="external">acetaminophen-aspirin-caffeine</a> (250 mg-250 mg-65 mg). (See <a class="local">'Combination analgesics with caffeine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of limited or dubious benefit</strong> – We recommend <strong>against</strong> the routine use of opioids or barbiturates for treatment of TTH. We reserve use of combination analgesic therapy with these agents for highly selected patients with episodic TTH who are unresponsive to simple analgesics or combination analgesics with <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> or those who are unable take NSAIDs, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, or <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>. Prerequisites of therapy for such patients include establishment of dose limits and monitoring of therapy. (See <a class="local">'Limited role of combination analgesics containing barbiturates or opioids'</a> above.)</p><p></p><p class="bulletIndent1">We do <strong>not</strong> use muscle relaxants due to lack of efficacy and risk of adverse effects. The benefit of triptans, local injections, and nonpharmacologic therapies is uncertain. (See <a class="local">'Treatments of uncertain or dubious benefit'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dowson AJ, Tepper SJ, Baos V, et al. Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Curr Med Res Opin 2004; 20:1125.</a></li><li class="breakAll">World Health Organization. Atlas of headache disorders and resources in the world 2011. https://www.who.int/mental_health/management/atlas_headache_disorders/en/ (Accessed on November 02, 2020).</li><li><a class="nounderline abstract_t">Steiner TJ, Lange R, Voelker M. Aspirin in episodic tension-type headache: placebo-controlled dose-ranging comparison with paracetamol. Cephalalgia 2003; 23:59.</a></li><li><a class="nounderline abstract_t">von Graffenried B, Nüesch E. Non-migrainous headache for the evaluation of oral analgesics. Br J Clin Pharmacol 1980; 10 Suppl 2:225S.</a></li><li><a class="nounderline abstract_t">Moore RA, Derry S, Wiffen PJ, et al. Evidence for efficacy of acute treatment of episodic tension-type headache: methodological critique of randomised trials for oral treatments. Pain 2014; 155:2220.</a></li><li><a class="nounderline abstract_t">Bendtsen L, Evers S, Linde M, et al. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol 2010; 17:1318.</a></li><li><a class="nounderline abstract_t">Lenaerts ME. Pharmacotherapy of tension-type headache (TTH). Expert Opin Pharmacother 2009; 10:1261.</a></li><li><a class="nounderline abstract_t">Verhagen AP, Damen L, Berger MY, et al. [Treatment of tension type headache: paracetamol and NSAIDs work: a systematic review]. Ned Tijdschr Geneeskd 2010; 154:A1924.</a></li><li><a class="nounderline abstract_t">Stephens G, Derry S, Moore RA. Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev 2016; :CD011889.</a></li><li><a class="nounderline abstract_t">Derry S, Wiffen PJ, Moore RA, Bendtsen L. Ibuprofen for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev 2015; :CD011474.</a></li><li><a class="nounderline abstract_t">Veys L, Derry S, Moore RA. Ketoprofen for episodic tension-type headache in adults. Cochrane Database Syst Rev 2016; 9:CD012190.</a></li><li><a class="nounderline abstract_t">Martínez-Martín P, Raffaelli E Jr, Titus F, et al. Efficacy and safety of metamizol vs. acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study. Cephalalgia 2001; 21:604.</a></li><li><a class="nounderline abstract_t">Lange R, Lentz R. Comparison ketoprofen, ibuprofen and naproxen sodium in the treatment of tension-type headache. Drugs Exp Clin Res 1995; 21:89.</a></li><li><a class="nounderline abstract_t">Diamond S. Ibuprofen versus aspirin and placebo in the treatment of muscle contraction headache. Headache 1983; 23:206.</a></li><li><a class="nounderline abstract_t">van Gerven JM, Schoemaker RC, Jacobs LD, et al. Self-medication of a single headache episode with ketoprofen, ibuprofen or placebo, home-monitored with an electronic patient diary. Br J Clin Pharmacol 1996; 42:475.</a></li><li><a class="nounderline abstract_t">Kubitzek F, Ziegler G, Gold MS, et al. Low-dose diclofenac potassium in the treatment of episodic tension-type headache. Eur J Pain 2003; 7:155.</a></li><li><a class="nounderline abstract_t">Prior MJ, Cooper KM, May LG, Bowen DL. Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomized, double-blind, placebo-controlled trial. Cephalalgia 2002; 22:740.</a></li><li><a class="nounderline abstract_t">Pini LA, Del Bene E, Zanchin G, et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium. J Headache Pain 2008; 9:367.</a></li><li><a class="nounderline abstract_t">Mehlisch DR, Weaver M, Fladung B. Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache 1998; 38:579.</a></li><li><a class="nounderline abstract_t">Dahlöf CG, Jacobs LD. Ketoprofen, paracetamol and placebo in the treatment of episodic tension-type headache. Cephalalgia 1996; 16:117.</a></li><li><a class="nounderline abstract_t">Schachtel BP, Furey SA, Thoden WR. Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache. J Clin Pharmacol 1996; 36:1120.</a></li><li><a class="nounderline abstract_t">Packman B, Packman E, Doyle G, et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension-type headache. Headache 2000; 40:561.</a></li><li><a class="nounderline abstract_t">Miller DS, Talbot CA, Simpson W, Korey A. A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache 1987; 27:392.</a></li><li><a class="nounderline abstract_t">Steiner TJ, Lange R. Ketoprofen (25 mg) in the symptomatic treatment of episodic tension-type headache: double-blind placebo-controlled comparison with acetaminophen (1000 mg). Cephalalgia 1998; 18:38.</a></li><li><a class="nounderline abstract_t">Lampl C, Voelker M, Steiner TJ. Aspirin is first-line treatment for migraine and episodic tension-type headache regardless of headache intensity. Headache 2012; 52:48.</a></li><li><a class="nounderline abstract_t">Derry S, Wiffen PJ, Moore RA. Aspirin for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev 2017; 1:CD011888.</a></li><li><a class="nounderline abstract_t">Langemark M, Olesen J. Effervescent ASA versus solid ASA in the treatment of tension headache. A double-blind, placebo controlled study. Headache 1987; 27:90.</a></li><li><a class="nounderline abstract_t">Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes. Cephalalgia 2004; 24:483.</a></li><li><a class="nounderline abstract_t">Tfelt-Hansen P, Langemark M. Parenteral treatment of episodic tension-type headache. Is there sufficient evidence? Headache 2014; 54:922.</a></li><li><a class="nounderline abstract_t">Weinman D, Nicastro O, Akala O, Friedman BW. Parenteral treatment of episodic tension-type headache: a systematic review. Headache 2014; 54:260.</a></li><li><a class="nounderline abstract_t">Harden RN, Rogers D, Fink K, Gracely RH. Controlled trial of ketorolac in tension-type headache. Neurology 1998; 50:507.</a></li><li><a class="nounderline abstract_t">Kaniecki R, Ruoff G, Smith T, et al. Prevalence of migraine and response to sumatriptan in patients self-reporting tension/stress headache. Curr Med Res Opin 2006; 22:1535.</a></li><li><a class="nounderline abstract_t">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.</a></li><li><a class="nounderline abstract_t">Rasmussen BK. Epidemiology of headache. Cephalalgia 1995; 15:45.</a></li><li><a class="nounderline abstract_t">Diamond S, Freitag FG. The use of ibuprofen plus caffeine to treat tension-type headache. Curr Pain Headache Rep 2001; 5:472.</a></li><li><a class="nounderline abstract_t">Diamond S, Balm TK, Freitag FG. Ibuprofen plus caffeine in the treatment of tension-type headache. Clin Pharmacol Ther 2000; 68:312.</a></li><li><a class="nounderline abstract_t">Cerbo R, Centonze V, Grazioli I, et al. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine in the treatment of episodic tension-type headache: a double-blind, randomized, nimesulide-controlled, parallel group, multicentre trial. Eur J Neurol 2005; 12:759.</a></li><li><a class="nounderline abstract_t">Diener HC, Pfaffenrath V, Pageler L, et al. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005; 25:776.</a></li><li><a class="nounderline abstract_t">Migliardi JR, Armellino JJ, Friedman M, et al. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 1994; 56:576.</a></li><li><a class="nounderline abstract_t">Lipton RB, Diener HC, Robbins MS, et al. Caffeine in the management of patients with headache. J Headache Pain 2017; 18:107.</a></li><li><a class="nounderline abstract_t">Haag G, Diener HC, May A, et al. Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Österreichische Kopfschmerzgesellschaft (ÖKSG) and the Schweizerische Kopfwehgesellschaft (SKG). J Headache Pain 2011; 12:201.</a></li><li><a class="nounderline abstract_t">Zhang WY. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Saf 2001; 24:1127.</a></li><li><a class="nounderline abstract_t">Kaniecki RG. Tension-type headache. Continuum (Minneap Minn) 2012; 18:823.</a></li><li><a class="nounderline abstract_t">Scher AI, Lipton RB, Stewart WF, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia 2010; 30:321.</a></li><li><a class="nounderline abstract_t">Bentivegna E, Luciani M, Paragliola V, et al. Recent advancements in tension-type headache: a narrative review. Expert Rev Neurother 2021; 21:793.</a></li><li><a class="nounderline abstract_t">Brennum J, Kjeldsen M, Olesen J. The 5-HT1-like agonist sumatriptan has a significant effect in chronic tension-type headache. Cephalalgia 1992; 12:375.</a></li><li><a class="nounderline abstract_t">Brennum J, Brinck T, Schriver L. Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. Eur J Neurol 1996; 3:23.</a></li><li><a class="nounderline abstract_t">Cady RK, Gutterman D, Saiers JA, Beach ME. Responsiveness of non-IHS migraine and tension-type headache to sumatriptan. Cephalalgia 1997; 17:588.</a></li><li><a class="nounderline abstract_t">Lipton RB, Cady RK, Stewart WF, et al. Diagnostic lessons from the spectrum study. Neurology 2002; 58:S27.</a></li></ol></div><div id="topicVersionRevision">Topic 3358 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265257" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265257" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12534583" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Aspirin in episodic tension-type headache: placebo-controlled dose-ranging comparison with paracetamol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7002183" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Non-migrainous headache for the evaluation of oral analgesics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25139586" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evidence for efficacy of acute treatment of episodic tension-type headache: methodological critique of randomised trials for oral treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20482606" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : EFNS guideline on the treatment of tension-type headache - report of an EFNS task force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463068" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pharmacotherapy of tension-type headache (TTH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20699021" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : [Treatment of tension type headache: paracetamol and NSAIDs work: a systematic review].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27306653" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26230487" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ibuprofen for acute treatment of episodic tension-type headache in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27654948" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ketoprofen for episodic tension-type headache in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11472387" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy and safety of metamizol vs. acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7555617" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison ketoprofen, ibuprofen and naproxen sodium in the treatment of tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6355010" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ibuprofen versus aspirin and placebo in the treatment of muscle contraction headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8904620" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Self-medication of a single headache episode with ketoprofen, ibuprofen or placebo, home-monitored with an electronic patient diary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12600797" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Low-dose diclofenac potassium in the treatment of episodic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12421160" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18815727" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11398300" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ketoprofen, acetaminophen, and placebo in the treatment of tension headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8665578" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Ketoprofen, paracetamol and placebo in the treatment of episodic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9013368" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10940094" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3308770" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9601623" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ketoprofen (25 mg) in the symptomatic treatment of episodic tension-type headache: double-blind placebo-controlled comparison with acetaminophen (1000 mg).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21883198" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Aspirin is first-line treatment for migraine and episodic tension-type headache regardless of headache intensity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28084009" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Aspirin for acute treatment of episodic tension-type headache in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3553071" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effervescent ASA versus solid ASA in the treatment of tension headache. A double-blind, placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15154858" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797487" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Parenteral treatment of episodic tension-type headache. Is there sufficient evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24433525" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Parenteral treatment of episodic tension-type headache: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9484382" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Controlled trial of ketorolac in tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16870078" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevalence of migraine and response to sumatriptan in patients self-reporting tension/stress headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7758098" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Epidemiology of headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560814" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The use of ibuprofen plus caffeine to treat tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11014413" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ibuprofen plus caffeine in the treatment of tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16190913" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine in the treatment of episodic tension-type headache: a double-blind, randomized, nimesulide-controlled, parallel group, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162254" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7955822" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Caffeine as an analgesic adjuvant in tension headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29067618" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Caffeine in the management of patients with headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21181425" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), theÖsterreichische Kopfschmerzgesellschaft (ÖKSG) and the Schweizerische Kopfwehgesellschaft (SKG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11772146" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A benefit-risk assessment of caffeine as an analgesic adjuvant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22868544" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19614708" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34128449" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Recent advancements in tension-type headache: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1335361" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The 5-HT1-like agonist sumatriptan has a significant effect in chronic tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9251874" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Responsiveness of non-IHS migraine and tension-type headache to sumatriptan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12011271" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Diagnostic lessons from the spectrum study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
